NeuBase Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

NeuBase Therapeutics

21/12/2022 13:41

* NeuBase Therapeutics Inc  NBSE.OQ  reported a quarterly
adjusted
loss of 24 cents​​ per share for the quarter ended in September.
The mean expectation of three analysts for the quarter was for a
loss of 28 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * NeuBase Therapeutics Inc's reported EPS for the quarter
was a
loss of 24 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * NeuBase Therapeutics Inc shares had fallen by 51.9% this
quarter and lost 93.2% so far this year.
    * The company reported a quarterly loss of $7.63 million.
    * Wall Street's median 12-month price target for NeuBase
Therapeutics Inc is $8.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data December
21 at 01:41 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.28          -0.24          Beat
 Jun. 30 2022      -0.30          -0.26          Beat
 Mar. 31 2022      -0.23          -0.30          Missed
 Dec. 31 2021      -0.23          -0.24          Missed